Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.

Cureus · 2022 · PMC8905549 · PMID 35282535

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

only marginally significantno p-value reported

Although these results were only marginally significant, a similar phenomenon was observed in 48 patients with PTEN-low tumors who shoed a higher mPFS while on Ipatsertib/paclitaxel compared to placebo [6.2 months vs. 3.7 months; HR: 0.59 (0.26-1.32), p=0.18].

also in 5,076 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.